Therapure Drug Development
Therapure currently has four therapeutic products in its drug development pipeline.
Indication: Post-Liver transplant & acute and chronic HCV
We have developed a smarter way to target HCV infections with the best available drug. TBI 301 is a conjugate of hemoglobin and ribavirin that selectively targets the liver. The combination is more tolerable and powerful than ribavirin alone and has the potential to more effectively treat this widespread, serious and difficult to treat disease. TBI 301 is in position to commence human clinical trials following formal PK/Tox studies.
uptake of radiolabeled hemoglobin
TBI 303 is a novel, proprietary protein modification technology designed to improve the performance of existing protein-based therapeutics through an increase in half-life. Screening studies currently underway at Therapure are designed to broaden the platform to a wide range of proteins.
Indication: Chemotherapy-Induced Anemia
Approximately 40% of people suffering from anemia, as a result of chemotherapy, do not respond to the current standard treatment, Erythropoietin. TBI 304 is a monoclonal antibody that mimics the natural ability of hemoglobin to stimulate blood forming stem cells to produce red blood cells. TBI 304 is currently in preclinical proof of concept stage.
Our Drug Development Team
Therapure's drug development team is led by Dr. David Bell, Vice President of Drug Development and Chief Scientific Officer and Dr. Gord Adamson, Director of Drug Development with support from Dr. Steve Brookes, Manager of Drug Development and Ms. Kate Matthews, Group Leader of Cell and Molecular Biology.